Cargando…
Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours
Somatostatin has been identified as having anti-proliferative, anti-angiogenic and pro-apoptotic actions in many tumour systems, and these effects are mediated through a family of five transmembrane G-protein coupled SRIF receptors. Ovarian cancer is the commonest gynaecological malignancy in the UK...
Autores principales: | Hall, G H, Turnbull, L W, Richmond, I, Helboe, L, Atkin, S L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2364287/ https://www.ncbi.nlm.nih.gov/pubmed/12085262 http://dx.doi.org/10.1038/sj.bjc.6600284 |
Ejemplares similares
-
Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium
por: Adams, R L, et al.
Publicado: (2005) -
Identification of mRNAs differentially-expressed between benign and malignant breast tumour cells
por: Liu, D, et al.
Publicado: (2002) -
Alteration of somatostatin receptor 2 expression in canine mammary gland
tumor
por: SAKAI, Kosei, et al.
Publicado: (2015) -
The coxsackievirus and adenovirus receptor acts as a tumour suppressor in malignant glioma cells
por: Kim, M, et al.
Publicado: (2003) -
Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker
por: Hoffman, B R, et al.
Publicado: (2002)